Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 27 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaRecruitingNCT03465592Phase 1/2
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsRecruitingNCT03449238Phase 1/2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaRecruitingNCT03406247Phase 2
• Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive GlioblastomaRecruitingNCT03383978Phase 1
• Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without NephroureterectomyNot yet recruitingNCT03345134Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic CancerRecruitingNCT03295227Phase 1
• Renal Adjuvant MultiPle Arm Randomised TrialRecruitingNCT03288532Phase 3
• Combination of TATE and PD-1 Inhibitor in Liver CancerRecruitingNCT03259867Phase 2
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2
• SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingNCT03166397Phase 2
• SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingNCT03138161Phase 1/2
• Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaRecruitingNCT03080974Phase 2
• Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingNCT03026140Phase 2
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
• Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory MalignanciesRecruitingNCT02961101Phase 1/2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedNCT06790303Phase 2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
• A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male ParticipantsCompletedNCT06309394Phase 1Results posted
• A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyTerminatedNCT06267001Phase 3Results posted
• A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionActive, not recruitingNCT06212752Phase 3Results posted
• Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsCompletedNCT06119217Phase 2Results posted
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted
• A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06094296Phase 2Results posted
• Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedNCT06046482Phase 2Results posted
• A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationTerminatedNCT06039384Phase 1Results posted
• Induction Chemo-Nivo in Unresectable Stage III NSCLCTerminatedNCT06003075Phase 2Results posted
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaTerminatedNCT05921760Phase 1/2Results posted
• A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedNCT05908786Phase 1/2Results posted
• A Study of XmAb23104 in People With SarcomaTerminatedNCT05879185Phase 2Results posted
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsTerminatedNCT05787496Phase 1Results posted
• Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCTerminatedNCT05776875Phase 2Results posted
• A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerCompletedNCT05775289Phase 2Results posted
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedNCT05764395Phase 2Results posted
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast CancerTerminatedNCT05756166Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
• Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain MetastasesTerminatedNCT05746481Phase 2Results posted
• A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Phase 3Results posted
• Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
• Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialActive, not recruitingNCT05715281Phase 2Results posted
• EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingNCT05715216Phase 2Results posted
• A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCompletedNCT05712356Phase 2Results posted
• Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical PracticeTerminatedNCT05694013Phase 2/3Results posted
• Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLCTerminatedNCT05691829Phase 2Results posted
• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsCompletedNCT05661578Phase 2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaTerminatedNCT05634577Phase 2Results posted
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT05609370Phase 1/2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedNCT05600309Phase 3Results posted
• Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerCompletedNCT05577702Phase 2Results posted
• Combination Immunotherapy in Colorectal CancerCompletedNCT05571293Phase 2Results posted
• A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerTerminatedNCT05543629Phase 1/2Results posted
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedNCT05542342Phase 2Results posted
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid ArthritisTerminatedNCT05516758Phase 2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedNCT05508867Phase 2Results posted
• A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedNCT05469178Phase 1/2Results posted
• Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Phase 2Results posted
• Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)CompletedNCT05446870Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic CancersCompletedNCT05383170Phase 1/2Results posted
• Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersCompletedNCT05379972Phase 2Results posted
• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedNCT05337137Phase 1/2Results posted
• A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerTerminatedNCT05328908Phase 3Results posted
• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results posted
• An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaTerminatedNCT05315713Phase 1/2Results posted
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminatedNCT05308901Phase 2Results posted
• A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedNCT05297565Phase 3Results posted
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05287113Phase 2Results posted
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerTerminatedNCT05263492Phase 2Results posted
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsTerminatedNCT05256381Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction CarcinomaTerminatedNCT05251948Phase 1/2Results posted
• Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaTerminatedNCT05249569Phase 2Results posted
• Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.CompletedNCT05243862Phase 2Results posted
• 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic AdenocarcinomaTerminatedNCT05239182Phase 2Results posted
• Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Phase 3Results posted
• Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Active, not recruitingNCT05224141Phase 3Results posted
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT05216835Phase 1Results posted
• Study of Combined Decompressive Spine Radiosurgery and PembrolizumabTerminatedNCT05204290Early Phase 1Results posted
• A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive, not recruitingNCT05203445Phase 2Results posted
• Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
• Regorafenib and Durvalumab for the Treatment of High-Risk Liver CancerActive, not recruitingNCT05194293Phase 2Results posted
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesTerminatedNCT05191472Phase 2Results posted
• A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerCompletedNCT05171777Phase 2Results posted

← Immune Checkpoint Inhibitors overview